Cargando…

The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer

microRNAs (miRNAs) play critical roles in cancer development and progression. This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) development. miR-138-5p was frequently downregulated in CRC tissues and was associated with advanced clinical stage, lymph node metastasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lian, Yu, Haibo, Yi, Shuijing, Peng, Xiaowei, Su, Peng, Xiao, Zhiming, Liu, Rui, Tang, Anliu, Li, Xiayu, Liu, Fen, Shen, Shourong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216728/
https://www.ncbi.nlm.nih.gov/pubmed/27248318
http://dx.doi.org/10.18632/oncotarget.9659
_version_ 1782491969303347200
author Zhao, Lian
Yu, Haibo
Yi, Shuijing
Peng, Xiaowei
Su, Peng
Xiao, Zhiming
Liu, Rui
Tang, Anliu
Li, Xiayu
Liu, Fen
Shen, Shourong
author_facet Zhao, Lian
Yu, Haibo
Yi, Shuijing
Peng, Xiaowei
Su, Peng
Xiao, Zhiming
Liu, Rui
Tang, Anliu
Li, Xiayu
Liu, Fen
Shen, Shourong
author_sort Zhao, Lian
collection PubMed
description microRNAs (miRNAs) play critical roles in cancer development and progression. This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) development. miR-138-5p was frequently downregulated in CRC tissues and was associated with advanced clinical stage, lymph node metastasis and poor overall survival. We found that miR-138-5p decreased expression of programmed cell death ligand 1 (PD-L1) through interaction with its PD-L1 3′ untranslated region. miR-138-5p also dramatically suppressed CRC cell growth in vitro and inhibited tumorigenesis in vivo. PD-L1 and miR-138-5p levels were inversely correlated in human CRC tumors, and miR-138-5p inhibited PD-L1 expression in tumor models. These results suggest that miR-138-5p is a tumor suppressor in CRC, and its effects are exerted at least partially through PD-L1 downregulation. Low miR-138-5p and high PD-L1 levels correlated with shorter overall CRC patient survival, indicating that miR-138-5p and PD-L1 may serve as CRC biomarkers for risk group assignment, optimal therapy selection and clinical outcome prediction. Targeting PD-L1, possibly by administering miR-138-5p mimics, might be a clinically effective anti-CRC therapeutic strategy.
format Online
Article
Text
id pubmed-5216728
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-52167282017-01-15 The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer Zhao, Lian Yu, Haibo Yi, Shuijing Peng, Xiaowei Su, Peng Xiao, Zhiming Liu, Rui Tang, Anliu Li, Xiayu Liu, Fen Shen, Shourong Oncotarget Research Paper microRNAs (miRNAs) play critical roles in cancer development and progression. This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) development. miR-138-5p was frequently downregulated in CRC tissues and was associated with advanced clinical stage, lymph node metastasis and poor overall survival. We found that miR-138-5p decreased expression of programmed cell death ligand 1 (PD-L1) through interaction with its PD-L1 3′ untranslated region. miR-138-5p also dramatically suppressed CRC cell growth in vitro and inhibited tumorigenesis in vivo. PD-L1 and miR-138-5p levels were inversely correlated in human CRC tumors, and miR-138-5p inhibited PD-L1 expression in tumor models. These results suggest that miR-138-5p is a tumor suppressor in CRC, and its effects are exerted at least partially through PD-L1 downregulation. Low miR-138-5p and high PD-L1 levels correlated with shorter overall CRC patient survival, indicating that miR-138-5p and PD-L1 may serve as CRC biomarkers for risk group assignment, optimal therapy selection and clinical outcome prediction. Targeting PD-L1, possibly by administering miR-138-5p mimics, might be a clinically effective anti-CRC therapeutic strategy. Impact Journals LLC 2016-05-27 /pmc/articles/PMC5216728/ /pubmed/27248318 http://dx.doi.org/10.18632/oncotarget.9659 Text en Copyright: © 2016 Zhao et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhao, Lian
Yu, Haibo
Yi, Shuijing
Peng, Xiaowei
Su, Peng
Xiao, Zhiming
Liu, Rui
Tang, Anliu
Li, Xiayu
Liu, Fen
Shen, Shourong
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
title The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
title_full The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
title_fullStr The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
title_full_unstemmed The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
title_short The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
title_sort tumor suppressor mir-138-5p targets pd-l1 in colorectal cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216728/
https://www.ncbi.nlm.nih.gov/pubmed/27248318
http://dx.doi.org/10.18632/oncotarget.9659
work_keys_str_mv AT zhaolian thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT yuhaibo thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT yishuijing thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT pengxiaowei thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT supeng thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT xiaozhiming thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT liurui thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT tanganliu thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT lixiayu thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT liufen thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT shenshourong thetumorsuppressormir1385ptargetspdl1incolorectalcancer
AT zhaolian tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT yuhaibo tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT yishuijing tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT pengxiaowei tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT supeng tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT xiaozhiming tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT liurui tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT tanganliu tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT lixiayu tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT liufen tumorsuppressormir1385ptargetspdl1incolorectalcancer
AT shenshourong tumorsuppressormir1385ptargetspdl1incolorectalcancer